Georgia Life Sciences Names 2025 Golden Helix Award Winners

Academic Innovators and Industry Leaders to be Honored at the Georgia Life Sciences Summit 

August 12, 2025 - The Georgia Life Sciences Golden Helix Awards celebrate excellence and achievement across Georgia’s life sciences ecosystem, recognizing the individuals, companies, and institutions making significant contributions to scientific discovery, health innovation, and economic growth in the state and beyond. 


This year’s winners will be honored at the welcome reception and awards ceremony on day one of the Georgia Life Sciences Summit, August 26-27 at the Sandy Springs Performing Arts Center.


We are pleased to announce this year’s slate of 2025 Golden Helix Award winners: 


PHOENIX AWARD: Boehringer-Ingelheim / University of Georgia  for the Sustainable Development Excellence Certificate Program 

This award, sponsored by the Metro Atlanta Chamber, celebrates an industry/academic collaboration, or other allied partnership, that demonstrate strength, tenacity, and leadership. Like the mythical phoenix, together they exemplify how strategic partnerships can accelerate discovery, fuel commercialization, and create meaningful impact for patients and communities. 


INNOVATION AWARD: Myomatrix

Presented to an institution, team, or individual whose innovation goes beyond the traditional paradigms and has the potential to significantly impact human health, agriculture, or environmental sustainability. Eligible innovations may include—but are not limited to—advancements in biotechnology, pharmaceuticals, diagnostics, medical devices, digital health, or life science-related AI and data platforms. 


DEAL OF THE YEAR AWARD

  • Andson Biotech (Private Financing), biotools company revolutionizing sample preparation for mass spectrometry workflows, for closing a $3.6M seed round led by industry veterans and expanding from three to ten employees while launching its DynaChip X1 platform into commercial markets. 
  • Micron Biomedical (Private Financing), for securing $16M to expand manufacturing of its needle-free vaccine delivery technology and advance multiple vaccine candidates toward commercialization.
  • Moonlight Therapeutics (Private Financing), or closing its first equity round, Series A, co-led by Portal Innovations, to advance its novel intradermal allergen immunotherapy platform for treating food allergies, beginning with MOON101 for peanut allergy.
  • Synaptrix (Private Financing), a medical device company developing the groundbreaking NOVABLOC™ system for drug-free postoperative pain management, for raising $13M in Series A funding led by Hatteras Venture Partners to support pivotal studies, regulatory submission, and commercialization.
  • ANI Pharmaceuticals (Acquisition) for its definitive agreement to acquire Alimera Sciences, for $453M, expanding its global footprint and portfolio to three commercial rare disease assets.
  • Stryker (Acquisition), for its definitive agreement to acquire Artelon, expanding its portfolio of soft tissue fixation solutions for orthopedic surgeons.
  • Duracell (Economic Development), for selecting Georgia as the site of its new North American R&D headquarters, further strengthening the state’s life sciences and advanced manufacturing ecosystem. 

Presented to a company or institution who has made the most significant transaction of the year (between January 1, 2024-March 31, 2025), a deal that exemplifies strategic vision, market influence, and long-term value creation. Whether it’s a transformative partnership, acquisition, licensing agreement, IPO, or major funding round, this deal represents a defining moment for the companies involved and a milestone for the state’s biotech ecosystem.  

 

COMMUNITY AWARD:

  • ARCS Foundation – Atlanta
  • Jeffrey Gray, Founder and CEO, AgeTech Atlanta
  • Christopher Kunney, Managing Partner and Digital Transformation Strategist, IOTech Consulting, LLC
  • Lisa Middleton, Ph.D., Director, Scientific Affairs, Georgia Cancer Center/Augusta University

Presented to a life sciences organization or individual that has demonstrated continuous commitment to making a positive, lasting impact on their local community. This award recognizes organizations/ individuals that go beyond their day-to-day operations through career development initiatives, outreach programs, patient advocacy, corporate philanthropy, or other significant community contribution.

 

EMERGING LEADER OF THE YEAR AWARD: Benjamin Siciliano, PhD, Radyus Research 

Presented to an individual in the first decade of their career whose achievements are significantly contributing to or transforming the life sciences industry. 


TEACHER OF THE YEAR AWARD: Amanda Barrett, Marietta High School 

Presented to a Georgia biotechnology high school teacher who exhibits innovative teaching, mentorship, and unwavering dedication to inspire the next generation of thinkers, problem-solvers, and future leaders in STEM/ biotechnology.


LEGISLATOR OF THE YEAR AWARD: Senator Chuck Hufstetler, 52nd District, Rome

Honors select legislators in recognition of their leadership in advancing federal and state policies to promote life sciences research, investment, and innovation. 


Winners are selected by the Golden Helix Awards Committee, a select group of leaders from Georgia’s life sciences, academic, and business communities who are responsible for identifying and recommending the most impactful individuals, companies, and organizations for recognition at the Golden Helix Awards. The committee reviews nominations across categories including scientific advancement, public policy, entrepreneurship, education, and community impact, aligning with the mission of the Golden Helix Awards to honor those whose ideas and achievements are leading the way in health and science.


To register for the summit, click here.

April 1, 2026
Atlanta, GA (April 1, 2026) – Georgia Life Sciences (GLS) is proud to announce that Saisurya Lakkimsetti, a junior at Lakeside High School in Columbia County, has been named the winner of the 2026 Georgia BioGENEius Challenge. The Georgia BioGENEius Challenge took place, as part of the statewide Georgia Science and Engineering Fair (GSEF) at the Classic Center in Athens, Georgia. Forty-seven students from across Georgia competed for this year’s title and cash prize. Jaehyeon Lee, an 11th-grade student from Walton High School, was named runner-up in this year’s competition. The Georgia BioGENEius Challenge recognizes outstanding high school students who are conducting innovative biotechnology research with real-world applications. This year’s top projects, presented in the Global Healthcare Challenge track, demonstrated exceptional scientific rigor and forward-thinking potential in addressing critical healthcare challenges. Saisurya’s research focuses on identifying potential inhibitors for Endocan, a protein known to play a role in glioblastoma tumor growth. Using advanced computational modeling techniques—including AlphaFold and molecular docking tools—she screened thousands of small molecules to identify compounds that may block tumor-promoting signaling pathways. Her work identified several promising candidates that could serve as a foundation for future drug development targeting glioblastoma. Jaehyeon’s project investigates how varying glucose concentrations affect regeneration in planaria, modeling impaired wound healing in diabetic conditions. By testing graded glucose environments and measuring regeneration indicators such as growth and differentiation, Jaehyeon demonstrated that lower glucose levels enhance regeneration while higher levels inhibit healing. The study establishes a model to better understand hyperglycemia’s impact on diabetic wound healing. “The work by these students is a powerful example of the innovation and determination we see in Georgia’s next generation of life sciences leaders,” said Maria Thacker Goethe, President and CEO of Georgia Life Sciences. “The BioGENEius Challenge is critical because it provides students with a platform to apply cutting-edge science to real-world problems, while also strengthening the future workforce that will drive breakthroughs in healthcare, biotechnology, and beyond.” The Georgia BioGENEius Challenge is part of Georgia Life Sciences’ broader commitment to advancing workforce development and fostering innovation across the state’s rapidly growing life sciences ecosystem. Judging the 2026 Georgia BioGENEius Challenge: Ian Biggs; Ralph Cordell, CDC; Alex Harvey, ViaMune; Jamie Graham, Smith Gambrell Russell; and Evan Scullin, LuminiSci.
March 24, 2026
Georgia Life Sciences is thrilled to be featured in the very first Atlanta edition of Inside Medicine . This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. Also in the issue, GLS's Kennedy Dumas is featured, sharing her journey on how observation and research evolved into a powerful practice of journaling. As the founder of Stationery Black, she creates notebooks designed to showcase, uplift, and inspire people of color. Read the full article here.
March 24, 2026
A new national outlook on the life sciences real estate market is reinforcing what many in Georgia’s ecosystem have been building toward: a more disciplined, workforce-driven, and manufacturing-focused future for the industry. CBRE’s 2026 U.S. Life Sciences Market Outlook points to a sector in transition—moving away from rapid, speculative expansion toward a more measured phase defined by targeted growth, capital efficiency, and long-term sustainability. For Georgia, these trends are not just informative—they are validating. A Market Reset Creates Opportunity After several years of rapid expansion in major coastal markets, the national lab space market is recalibrating. Construction has slowed significantly, and vacancy rates—while still elevated—are stabilizing. This shift favors emerging markets like Georgia that have taken a more measured approach to growth. Rather than contending with oversupply, Georgia is well-positioned to scale intentionally—aligning infrastructure, workforce, and industry demand in a way that supports long-term success. Manufacturing and Scale-Up Are Driving Growth One of the clearest signals from the CBRE report is the increasing role of large pharmaceutical and biomanufacturing investments in driving demand. This aligns directly with Georgia’s recent momentum. From major facility expansions to increased interest in onshoring and domestic production, the Southeast—and Georgia in particular—is becoming a destination for advanced manufacturing in the life sciences. The Georgia Life Sciences Roadmap has consistently emphasized this opportunity: Strengthening biomanufacturing capacity Building workforce pipelines to support production scale Positioning Georgia as a hub for both innovation and commercialization Workforce as the Differentiator As capital becomes more selective and companies prioritize execution, talent—not space—is emerging as the defining constraint. Georgia’s investments in workforce development, including partnerships with the Technical College System of Georgia and the Georgia Bioscience Training Center, position the state to meet this moment. Through coordinated efforts across education, industry, and government, Georgia is building the kind of workforce infrastructure that enables companies to not only locate here—but to grow here. A Converging Ecosystem Another key trend highlighted in the report is the convergence of life sciences with adjacent sectors such as digital health, robotics, and advanced technologies. This is an area where Atlanta stands out. With strengths in medtech, health IT, and data-driven healthcare solutions, the region offers a broader definition of “life sciences”—one that reflects where the industry is headed, not where it has been. Looking Ahead The national life sciences sector is entering a new phase—one that rewards strategic alignment, ecosystem coordination, and long-term investment. Georgia is not starting from scratch in this environment. It has been building toward it. The Georgia Life Sciences Roadmap anticipated many of these shifts, prioritizing: Workforce development Manufacturing and scale-up capacity Industry-academic collaboration Capital and commercialization pathways As national trends continue to evolve, Georgia’s focus on disciplined, intentional growth positions the state—and the broader Southeast—as a compelling partner in the next chapter of the life sciences industry.  Read report - CBRE Chapter 9, Life Sciences - U.S. Real Estate Market Outlook 2026 https://www.cbre.com/insights/books/us-real-estate-market-outlook-2026/life-sciences
MORE POSTS